Treatment with cervicovaginal vaccination with HPV16 E7aa4362 peptide/CPG-1826 could induce the production of CD103+ CD8+ TRM cells, and; subsequently, the number of CD8+ T cells increased, resulting in suppressing tumor progression in the genital tract (Huang et al., 2022b). Here, CD8A is linked to neoplasm.